15th July 2011
Leading drug manufacturer Beximco Pharmaceuticals Ltd (BPL) has introduced new strength of etoricoxib, Ribox-120, for the management of pain associated with ankylosing spondylitis, acute gouty arthritis & dental procedure.
Ribox-120 is preparation of Etoricoxib 120mg. Etoricoxib is a COX-2 selective inhibitor (approx. 106.0 times more selective for COX-2 inhibition over COX-1). Ribox-120 is indicated for the symptomatic relief of ankylosing spondylitis, the pain and signs of inflammation associated with acute gouty arthritis and dental pain. As etoricoxib is a selective COX-2 inhibitor so it only act on pain & inflammation without interfering COX-1 mediated gastro protective functions. As a result, Ribox reduce pain & inflammation with better GI safety. Besides this Beximco Pharma already launched Ribox-60 & Ribox-90.